Amlodipine And Olmesartan Medoxomil Tablet
Product Images NDC 72162-2379

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Amlodipine And Olmesartan Medoxomil (NDC 72162-2379). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2 (Amlodipineolmesartanf2)

A line graph showing the probability of achieving diastolic blood pressure (DBP) below 90 mmHg at week 8 with LOCF. The graph compares placebo, Amlodipine 10 mg, Olmesartan Medoxomil 40 mg, and a combination of Amlodipine and Olmesartan Medoxomil 10/40 mg, plotted against baseline DBP values ranging from 95 to 110 mmHg.*

FDA Label Image

Figure 3 (Amlodipineolmesartanf3)

A line graph depicting the probability of achieving systolic blood pressure (SBP) below 130 mmHg at week 8 using Last Observation Carried Forward (LOCF). The graph compares placebo, amlodipine 10 mg, olmesartan medoxomil 40 mg, and the combination of amlodipine and olmesartan medoxomil 10/40 mg, showing the percentage of patients with SBP <130 mmHg over time.*

FDA Label Image

Figure 4 (Amlodipineolmesartanf4)

A line graph depicting the probability of achieving diastolic blood pressure (DBP) less than 80 mmHg at Week 8 with LOCF, comparing placebo, AML 10 mg, Olmesartan 40 mg, and combined amlodipine and olmesartan medoxomil 10/40 mg treatments across baseline DBP values from 95 to 110 mmHg.*

FDA Label Image

Figure 1 (Amlodipineolmesartanfigure1)

A line graph titled 'Probability of Achieving Systolic Blood Pressure (SBP) < 140 mmHg at Week 8 With LOCF.' The graph compares the percentage of patients reaching SBP < 140 mmHg across baseline SBP values (140-180 mmHg) for four groups: placebo, 0 mg/40 mg, Amlodipine 10 mg, and Amlodipine and olmesartan medoxomil 10/40 mg combination. The combination therapy shows the highest probability curve compared to others.*

FDA Label Image

Amlodipine Structure (Amlodipineolmesartanmedoxomilamlodipinestrc)

Chemical structure diagram of Amlodipine and Olmesartan Medoxomil, the active ingredients in the drug combination product AMLODIPINE AND OLMESARTAN MEDOXOMIL.*

FDA Label Image

Olmesartan Structure (Amlodipineolmesartanmedoxomilolmestrc)

Chemical structure of Amlodipine and Olmesartan Medoxomil, illustrating the molecular arrangement of atoms and bonds in the compound commonly used in oral tablets for hypertension.*

FDA Label Image

Label (Lbl721622379)

Label for Amlodipine and Olmesartan Medoxomil Tablets 5 mg/20 mg. The label includes the NDC 72162-2379-3 and states each tablet contains 6.9 mg Amlodipine Besylate USP equivalent to 5 mg Amlodipine and 20 mg Olmesartan Medoxomil USP. It is labeled for oral use with 30 tablets per package. The labeler is Bryant Ranch Prepack, and the manufacturer is Micro Labs Limited. Storage instructions and QR codes for package insert and dosage information are also displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.